

| | | |
|---|-------------------------------|--------------------------|
| Form PTO 1449 US Department of Commerce Patent and Trademark Office | ATTY DOCKET NO: P-IX 3536 | SERIAL NO. 09/339,922 |
| | APPLICANT: Huse and Wu | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT | FILING DATE: June 24, 1999 | GROUP: 1644 |

U.S. PATENT DOCUMENTS

| EXAM. INITIALS | DOCUMENT NUMBER | DATE | NAME | CLASS | SUB- CLASS | FILING DATE |
|-------------------|--------------------|---------|--------------|-------|---------------|----------------|
| PC | US 6,180,370 B1 | 1/30/01 | Queen et al. | 435 | 69.6 | 6/7/95 |
| | | | | | | |
| | | | | | | |
| | | | | | | |

FOREIGN PATENT DOCUMENTS

| EXAM. INITIALS | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUB- CLASS | TRANSLATION (YES/NO) |
|-------------------|--------------------|------|---------|-------|---------------|-------------------------|
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages)

| | |
|----|---|
| PC | Biotechnology Newswatch 1/16/95 p. 11-12 |
| PC | Biotechnology Newswatch 2/6/95 p. 11 |
| PC | Studnicka et al., "Human-engineered monoclonal antibodies retain full specific binding activity by preserving non-CDR complementarity-modulating residues," <u>Protein Engineering</u> 7:805-814 (1994) |
| | |

| | |
|-----------------------------------|-----------------|
| EXAMINER PHILIP GAMBER 4/15/02 | DATE CONSIDERED |
|-----------------------------------|-----------------|

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.